SCHEMBL5579013

SCHEMBL5579013

Cc1ccc(NC(=O)C2CCN(C(=O)OC(C)(C)C)CC2)c(Br)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.59
PTPN1 P18031 1/20 0.59
PTPN6 P29350 1/20 0.59
KMT2A Q03164 1/20 0.57
EPHX2 P34913 3/20 0.56
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
ABL1 P00519 1/20 0.52
RIN1 Q13671 1/20 0.52
LMNA P02545 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GPR119 Q8TDV5 3/20 0.50
STS P08842 3/20 0.50
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PABPC1 P11940 1/20 0.47
APOBEC3A P31941 1/20 0.47
EIF4H Q15056 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3171133 0.88 PTPN2 (0.58) PTPN2PTPN1PTPN6KMT2ANPC1
SCHEMBL860245 0.87 PTPN2 (0.57) PTPN2PTPN1PTPN6KMT2AEPHX2
SCHEMBL3186189 0.86 PTPN2 (0.56) PTPN2PTPN1PTPN6KMT2AEPHX2
SCHEMBL3171666 0.86 STS (0.56) PTPN2PTPN1PTPN6KMT2AEPHX2
SCHEMBL2108811 0.85 PTPN2 (0.55) PTPN2PTPN1PTPN6KMT2ANPC1
SCHEMBL3438844 0.85 PTPN2 (0.55) PTPN2PTPN1PTPN6KMT2AEPHX2
SCHEMBL3181308 0.85 PTPN2 (0.62) PTPN2PTPN1PTPN6KMT2AEPHX2
SCHEMBL6109107 0.85 GPR119 (0.64) KMT2AEPHX2NPC1RAB9ALMNA
SCHEMBL841859 0.84 PTPN2 (0.54) PTPN2PTPN1PTPN6KMT2AEPHX2
SCHEMBL26664390 0.83 PTPN2 (0.60) PTPN2PTPN1PTPN6KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed
EP-1716148-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF Arena Pharmaceuticals, Inc. (US) 2006-11-02 EP disclosed
WO-2005063745-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL PTPN2 3279/4885PTPN1 3148/4885PTPN6 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.